{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:47:18Z","timestamp":1779904038075,"version":"3.53.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s13555-022-00830-x","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T12:02:27Z","timestamp":1665230547000},"page":"2627-2635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis"],"prefix":"10.1007","volume":"12","author":[{"given":"Shuai","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5842-8080","authenticated-orcid":false,"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"830_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","volume":"23","author":"S Marrakchi","year":"2022","unstructured":"Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:13\u20139.","journal-title":"Am J Clin Dermatol"},{"key":"830_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","volume":"16","author":"S Kharawala","year":"2020","unstructured":"Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16:239\u201352.","journal-title":"Expert Rev Clin Immunol"},{"key":"830_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","volume":"23","author":"J Krueger","year":"2022","unstructured":"Krueger J, Puig L, Tha\u00e7i D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:51\u201364.","journal-title":"Am J Clin Dermatol"},{"key":"830_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15:907\u201319.","journal-title":"Expert Rev Clin Immunol"},{"key":"830_CR5","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/1346-8138.16022","volume":"48","author":"A Morita","year":"2021","unstructured":"Morita A, Kotowsky N, Gao R, Shimizu R, Okubo Y. Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the medical data vision claims database. J Dermatol. 2021;48:1463\u201373.","journal-title":"J Dermatol"},{"key":"830_CR6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.12070","volume":"53","author":"SE Choon","year":"2014","unstructured":"Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53:676\u201384.","journal-title":"Int J Dermatol"},{"key":"830_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","volume":"140","author":"A Johnston","year":"2017","unstructured":"Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140:109\u201320.","journal-title":"J Allergy Clin Immunol"},{"key":"830_CR8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45:1235\u201370.","journal-title":"J Dermatol"},{"key":"830_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","volume":"67","author":"A Robinson","year":"2012","unstructured":"Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2012;67:279\u201388.","journal-title":"J Am Acad Dermatol"},{"key":"830_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14814","volume":"34","author":"C Kromer","year":"2021","unstructured":"Kromer C, Loewe E, Schaarschmidt ML, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34: e14814.","journal-title":"Dermatol Ther"},{"key":"830_CR11","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385:2431\u201340.","journal-title":"N Engl J Med"},{"key":"830_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40257-021-00653-0","volume":"23","author":"AD Burden","year":"2022","unstructured":"Burden AD, Choon SE, Gottlieb AB, Navarini AA, Warren RB. Clinical disease measures in generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:39\u201350.","journal-title":"Am J Clin Dermatol"},{"key":"830_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043666","volume":"11","author":"SE Choon","year":"2021","unstructured":"Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11: e043666.","journal-title":"BMJ Open"},{"key":"830_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/1346-8138.14664","volume":"45","author":"A Morita","year":"2018","unstructured":"Morita A, Yamazaki F, Matsuyama T, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45:1371\u201380.","journal-title":"J Dermatol"},{"key":"830_CR15","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011\u20137.","journal-title":"J Dermatol"},{"key":"830_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"K Yamasaki","year":"2017","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741\u201351.","journal-title":"Br J Dermatol"},{"key":"830_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355\u201362.","journal-title":"J Dermatol"},{"key":"830_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/1346-8138.14294","volume":"45","author":"S Sano","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018;45:529\u201339.","journal-title":"J Dermatol"},{"key":"830_CR19","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/ijms22094344","volume":"22","author":"H Iznardo","year":"2021","unstructured":"Iznardo H, Puig L. Exploring the role of IL-36 cytokines as a new target in psoriatic disease. Int J Mol Sci. 2021;22:4344.","journal-title":"Int J Mol Sci"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00830-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T20:48:56Z","timestamp":1668804536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00830-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00830-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}